tivozanib 1.34 MG Oral Capsule [Fotivda]

Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.

Start free with Eleplan

Clinical drug

tivozanib 1.34 MG Oral Capsule [Fotivda]

1.34 MG · Oral Capsule · oral

A form of tivozanib →

tivozanib 1.34 MG Oral Capsule [Fotivda] — Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors. Strength, form, class, interactions & more.

tivozanib 1.34 MG Oral Capsule [Fotivda]

Active ingredient

Classification

Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorsKinase Inhibitor

Drug interactions

Tivozanib should not be used with strong CYP3A inducers due to reduced exposure and potential decrease in anti-tumor activity.

  • majorstrong CYP3A inducers — decreases tivozanib exposure and may reduce anti-tumor activity

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.